中文摘要：

目的 观察内生大麻素受体激动剂WIN 55,212-2对帕金森病左旋多巴相关异动症模型大鼠纹状体内单胺类神经递质释放的影响.方法 采用脑内微透析和高效液相色谱在线递质测量法观察WIN 55,212-2腹腔内注射对异动症模型大鼠左旋多巴相关异动症状和纹状体内单胺类神经递质释放的影响.结果 与溶剂注射相比,WIN 55,212-2注射显著抑制异动症模型大鼠左旋多巴皮下注射后的异动样症状（F1263=44.071,P＜0.001）,同时明显减少纹状体内多巴胺的释放（F1263=5.091,P＜0.05）.结论 纹状体内生大麻素受体可能通过抑制性的调节单胺类神经递质的释放来影响异动症模型大鼠的异动样症状.

英文摘要：

Objective To explore the effects of cannabinoid receptor agonist WIN 55,212-2 on striatal monoamine release in a rat model of L-DOPA-induced dyskinesia （LID）.Methods Effects of WIN 55,212-2 on striatal monoamine release in LID rats were observed by intracerebral microdialysis and high-performance liquid chromatography.Results The dyskinetic behavior related to L-DOPA was inhibited significantly by the injection of cannabinoid receptor agonist WIN 55,212-2 （F1263 =44.071,P＜0.001）,accompanied by significant decrease of striatal dopamine release （F12633-5.091,P＜0.05）.Conclusion The results suggest that cannabinoid receptor may be involved in mediating the dyskinetic behavior related to L-DOPA through the regulation of striatal monoamine release.